Celonic launches stand-alone GMP analytics portfolio
Challenging positions in upstream processing
Management and Team
Dr. Andreas Herrmann is President and Managing Director of Celonic AG and Celonic GmbH. In 1994, he received his PhD in biochemistry in the field of diseases of the central nervous system in Cologne. Already during graduation and afterwards, he led a laboratory in protein analytics at Cologne Center for Molecular Medicine. In Düsseldorf, he established a working group in the field of vascular gene therapy. Based on these efforts and resulting patents, Cardiogene (later Cardion) was founded in order to develop gene therapeutic and immunological products. In this company, Dr. Herrmann was responsible for the technological platforms and the complete production unit as well as preclinical analytics. He obtained his current position at Celonic in 2003 and re-structured the company towards a profitable company in the field of contract manufacturing.
Dr. Andreas Herrmann
Stefanie Herrmann is the head of the process development in Basel and member of Celonic’s senior management. She finished her diploma as a chemical engineer in 1997 und worked for the company AGS afterwards, especially being active in the field of fermentation and purification of enzymes. 1998 she joined Cardion. After a short while as project manager, she became responsible for the whole production unit, leading the areas of cell culture, process development and production of therapeutic proteins. She was appointed as the leader in production in 2003 and changed to head of process development in 2009. Thus, she provides more than ten years experience in biotechnology industry.
Dr. Karlheinz Landauer is in charge of operations at Celonic. After receiving his PhD from the Institute of Applied Microbiology at the University of Natural Resources and Life Sciences, Vienna and getting already some Biotech industry experience at this time at the institute he joined Ingeneon GmbH. He started as project leader for Biopharmaceutical product development and was promoted to Head of Manufacturing after taking on responsibilities in GMP documentation and process development. Finishing these first senior management experiences he moved on to gain further experience at Celltrion in South Korea. Coming back to Europe he joined Celonic in 2007 as product development program manager and Director R&D. Beginning 2011 he was appointed to COO of Celonic taking on one of the most responsible positions at Celonic. Based on his experiences at Celonic, Celltrion and Ingeneon, he has a broad experience from early lead optimization until late clinical development and GMP manufacturing for biologicals.
Dr. Roland Meisel is in charge of business development at Celonic. He received his PhD in organic chemistry in the field of carbohydrate and natural compound chemistry. He successfully finished add-on courses in medical and biochemistry. After collecting industry experience in different branches including management consulting (specialized in “Cycle Time Development” in chemical, pharmaceutical and IT branch) and experiences in project management for active medical device development, he specialized in Contract Manufacturing of biologic API and Drug Product. He was responsible member of the team that build up Contract Manufacturing business at Miltenyi Biotech GmbH and was Senior Business Development Manager at NextPharma Technology Holding Ltd. responsible for project acquisition in the area of pre-clinical and clinical development.
The Management Team